These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38878007)

  • 1. Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF.
    Weintraub WS; Kolm P; Dolman S; Alva M; Bhatt DL; Zhang Z
    JACC Heart Fail; 2024 Jun; ():. PubMed ID: 38878007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure.
    Kim J; Wang S; Sikirica S; Shafrin J
    J Comp Eff Res; 2024 Jun; 13(6):e230190. PubMed ID: 38771012
    [No Abstract]   [Full Text] [Related]  

  • 3. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
    Becher PM; Savarese G; Benson L; Dahlström U; Karlström P; Mol PGM; Metra M; Bhatt DL; Pitt B; Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):343-352. PubMed ID: 36718512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.
    Pitt B; Bhatt DL; Szarek M; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Ezekowitz JA; Sun F; Davies MJ; Verma S; Kosiborod MN; Steg PG;
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):879-889. PubMed ID: 37558385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
    Szarek M; Bhatt DL; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Banks P; Tesfaye E; Ezekowitz JA; Verma S; Pitt B;
    Ann Intern Med; 2021 Aug; 174(8):1065-1072. PubMed ID: 34152828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
    N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
    Aggarwal R; Bhatt DL; Szarek M; Cannon CP; McGuire DK; Inzucchi SE; Lopes RD; Davies MJ; Banks P; Pitt B; Steg PG
    J Am Coll Cardiol; 2023 Nov; 82(19):1842-1851. PubMed ID: 37914514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.
    Zhang W; Yu M; Cheng G
    Front Pharmacol; 2024; 15():1373314. PubMed ID: 38694909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality.
    Iyer N; Hussein S; Singareddy S; Sn VP; Jaramillo AP; Yasir M; Nath TS
    Cureus; 2023 Sep; 15(9):e45525. PubMed ID: 37868384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
    Long A; Salvo M
    Ann Pharmacother; 2023 Nov; ():10600280231211179. PubMed ID: 38014844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China.
    Chen P; Wang Y; Liu X; Yu J; Zheng X
    Am J Cardiovasc Drugs; 2024 May; 24(3):445-454. PubMed ID: 38619802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
    Pérez MS; Rodríguez-Capitán J; Requena-Ibáñez JA; Santos-Gallego CG; Urooj Zafar M; Escolar G; Mancini D; Mitter S; Lam D; Contreras JP; Fergus I; Atallah-Lajam F; Abascal V; Lala A; Moreno P; Moss N; Lerakis S; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2023 Jun; ():. PubMed ID: 37318685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How adoption of new pharmaceuticals can impact US health system reimbursement under alternative payment models: An economic model measuring the impact of sotagliflozin among patients with heart failure and diabetes.
    Shafrin J; Wang S; Kim J; Sikirica S; Sandhu AT
    J Manag Care Spec Pharm; 2024 Jul; ():1-11. PubMed ID: 38989709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial.
    Shah SR; Ali A; Ikram S
    Expert Rev Clin Pharmacol; 2021 May; 14(5):523-525. PubMed ID: 33764842
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
    Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
    JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK.
    Valentine WJ; Bottomley JM; Palmer AJ; Brändle M; Foos V; Williams R; Dormandy JA; Yates J; Tan MH; Massi-Benedetti M;
    Diabet Med; 2007 Sep; 24(9):982-1002. PubMed ID: 17593245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?
    Koufakis T; Mustafa OG; Tsimihodimos V; Ajjan RA; Kotsa K
    Drugs; 2021 Aug; 81(12):1365-1371. PubMed ID: 34232488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.